东北制药称产品价格已很低不涉及垄断

Northeast pharmaceuticals say the product prices have very low does not involve monopoly

　　东北制药相关人员称，案件并没有对公司的销量产生负面作用

Northeast pharmaceuticals related researchers said，The case of the sales of the company and not a negative role

　　7年前，华北制药、东北制药以及中国制药集团就收到了美国纽约东区联邦法院送达的反垄断集团诉讼传票及诉状，然而，让人颇为不解的是，直到7年后，该有关中国制药厂垄断维C市场案件才确定开审时间：2012年11月5日。

Seven years ago，North China pharmaceutical、Northeast pharmaceuticals and China pharmaceutical group received the east New York federal court on antitrust action group summons and complaint，however，Let people rather is uncertain，Until seven years later，The relevant Chinese pharmaceutical factory monopoly d C market to determine time court case：On nov. 5, 2012。

　　在这中间，国内相关公司的维C销售是否受到影响？对此，案件被告方之一东北制药相关人员告诉记者，案件并没有对公司的销量产生负面作用。“案件正在调查中，现在没法透露更多。”华北制药人士如是表示。

In the middle，Domestic related company d C sales are being affected？this，One of the case defence northeast pharmaceuticals related personnel told reporters，The case of the sales of the company and not a negative role。“The case is under investigation，Now can't reveal more。”North China pharmaceutical people so said。

　　“时隔7年才开庭审理，确实超出一般案件，此前没见过这么久的，不单单只是案件复杂的原因。”北京威诺律师事务所律师杨兆全在接受《证券日报》记者采访时表示，“如果案件中方败诉，则出口会受到很大影响，国内维C市场竞争无疑会更加激烈。上市公司利润会下降，小厂弱厂将更难生存”。

“After 7 years to trial，Do than general case，Previously haven't seen so long，Not just a case of complex reasons。”Beijing wei's lawyer in YangZhaoQuan accept《Securities daily》The reporter said in an interview，“If a case against China，The export will be badly affected，Domestic d C market competition, no doubt, will be more intense。The listed company profits will decline，Small factory weak factory will be more difficult to survive”。

　　拖了7年的诉讼

Drag the seven years of litigation

　　追根溯源，该案件要从2005年说起。华北制药2005年年报有这样一段话，公司下属子公司河北维尔康药业有限公司于2005年6月1日收到美国纽约东区联邦法院送达的反垄断集团诉讼传票及诉状等相关诉讼文件。该案件及相关诉讼已由美国相关司法机构交由美国纽约东区联邦法院审理。目前，该案件尚在审理程序过程中。

Traced back，The case from 2005 to start。North China pharmaceutical annual report 2005 have such a word，The company subordinate subsidiary hebei Wells kang pharmaceutical Co., LTD. In June 1, 2005 received the New York federal court of east to antitrust action group summons and complaint and related litigation document。The case and related litigation by the relevant judicial institutions has been to New York federal court side。At present，The case is still in the process of the trial procedure。

　　同时，东北制药、中国制药集团等纷纷收到此诉讼文件。

At the same time，Northeast pharmaceuticals、China pharmaceutical group in succession receive this litigation document。

　　只是，该案件之后便没了下文。于是，也就有了华北制药从2005年到2011年连续7年，在其年报中反复表述着：关于下属子公司河北维尔康制药有限公司及公司在美国涉及反垄断集团诉讼一事，目前该案件仍在审理程序过程中。

just，The case after they didn't below。so，Have a north China pharmaceutical from 2005 to 2011 for seven years，In its annual report and the expression of：A subsidiary of hebei Wells kang pharmaceutical Co., LTD. And the company involved in the United States the anti-monopoly group about the lawsuit，At present the case is still in the process of the trial procedure。

　　7月16日，记者致电华北制药董秘办，相关人员仍是那一句，“案件正在调查中，有专门部门在做，现在没法说这个事，涉及单位比较多，并不只是华北制药一家”。

July 16,，Reporters call north China pharmaceutical dong secret do，Related personnel is still that one sentence，“The case is under investigation，A special department，Now can't say this，Involves unit more，Not just a north China pharmaceutical”。

　　一个案件，7年的时间都在“审理程序过程中”。对此，业内人士表示，这个事件本身拖了很久，现在也只是定了一个初步的开审时间，能否在11月份按计划开审还不一定。

A case，Seven years of the time“In the process of the trial procedure”。this，People in the industry say，The incident itself dragged on for a long time，Now also just set a preliminary court time，Whether in November still not appearing as planned。

　　不过，北京威诺律师事务所律师杨兆全认为，时隔七年才开庭审理，确实超出一般案件。但既然已经确定了开庭时间，就不太可能改变。

but，Beijing wei's lawyer YangZhaoQuan think，After seven years to trial，Do than general case。But now that have set the court session，It is unlikely to change。

　　为什么一拖再拖？对此，记者试图从被告方寻找答案。东北制药相关人员告诉记者，并不知道为什么拖了这么久，可能中间涉及到方方面面的问题，确实不是很清楚。诉讼很早以前就有了，对于东北制药来说，诉讼主体是公司控股股东东北制药集团，和上市公司关系不大。

Why drag on？this，The reporter from defence trying to look for answers。Northeast pharmaceuticals related personnel told reporters，Don't know why drag for so long，Among possible involves a lot of aspects，Really is not very clear。Litigation long ago，Northeast pharmaceuticals for it，Litigation subject is the company controlling shareholders northeast pharmaceuticals group，Listed companies and the concern is not big。

　　华北制药仍是表示“目前无法说这件事情”。

North China pharmaceutical is still said“Currently not said this thing”。

　　若败诉维C出口将受影响

If losing d C exports will be affected

　　“此次如果中方败诉，维C今后出口将会受到很大影响，加上本身供大于求，国内维C市场竞争无疑会更加激烈。” 北京威诺律师事务所律师杨兆全对记者表示，涉及到具体企业盈利影响方面，利润会下降，大企业好一些，实力较小企业将更难生存。

“If the Chinese losing，D C future exports would be badly affected，And their excess supply，Domestic d C market competition, no doubt, will be more intense。” Beijing wei's lawyer YangZhaoQuan told reporters，Related to concrete influence corporate earnings，Profits fall，Big enterprise better，Strength smaller enterprise will be more difficult to survive。

　　本身国内维C市场盈利状况已经不是很乐观，2008年时，一度价格达到每公斤60元左右，高利润吸引很多企业投入维C项目。2010年，维C 产能过剩的问题就比较突出了，价格持续下滑，企业利润下降明显。只是，多数企业为了保证市场份额，虽然亏损但还在生产，导致该行业持续恶性发展。

Itself domestic d C market profits have not very optimistic，In 2008，Once the price reached 60 yuan per kilogram，High profits attract a lot of the enterprise put in d C project。2010 years，D C The problem of excess capacity is more outstanding，Prices continue to decline，Corporate profits are down significantly。just，Most of the enterprise in order to guarantee market share，Although losses but also in production，The industry to continue malignant development。

　　加上此次反垄断诉讼，维C的日子将更加难过。至于此案诉讼结果，杨兆全指出，胜诉或败诉涉及事实本身、证据、律师庭审技巧多方面，不好推测。

Add the antitrust litigation，D C day will be more sad。As for the case litigation results，YangZhaoQuan points out that，Win or lose involving the facts themselves、evidence、Many lawyers trial skills，That bad。

　　对美国提到的垄断市场问题，东北制药相关人员觉得很委屈，2008、2009年维生素C的价格都很高，现在已经低很多，美国认为行业垄断，但现在价格这么低，也涉及不到垄断的问题。

For the United States the problems mentioned to corner the market，Northeast pharmaceuticals related people feel very grievance，2008、2009 years of vitamin C prices were very high，Now has a lot of lower，The United States believes that the trades monopoly，But now the price so low，Also involve less than the problem of monopoly。

　　说到公司是否因此受到影响，她表示，2006年诉讼就有了，但之后几年并没有影响到公司维生素C的价格和销量。目前，维生素C的成本是每公斤25元，卖价在20元左右，行业普遍都是这个情况，但肯定不是这个案子引起的，市场供求关系决定的。

Said to the company is affected，She says she，2006 lawsuit，But for a few years and did not affect the vitamin C prices and sales。At present，Vitamin C is the cost of $25 per kg，Sale price in 20 yuan，Industry is the common，But certainly not the case cause，The relation between market supply and demand of the decision。

　　东北制药集团生产维生素C的主体是上市公司，但诉讼主体是集团。“公司并没有参与。”上述东北制药人员告诉记者。

Northeast pharmaceuticals group production vitamin C are the subject of listed companies，But litigation subject is the group。“The company and not involved。”The northeast pharmaceuticals personnel told reporters。

　　“若有损失，华北药业比较严重，上市公司直接参与了诉讼。”一位不愿具名的行业研究人士如是表示。

“If there is a loss，North China pharmaceutical industry is more serious，The listed company directly involved in the lawsuit。”An anonymous industry research people so said。

　　根据美国反垄断法，对经审理构成垄断行为的制裁非常严厉，赔偿金额为受害人所受损害的3倍。此次案件原告包括美国多家维C下游企业客户。被告涉及中国三家维C巨头，包括东北制药集团、华北制药、石家庄维生药业（隶属于石药集团）以及中国制药集团等等。

According to the American antitrust law，The trial to a monopoly behavior of sanctions was very severe，Compensation for the amount of the victim is three times as much damage。The case the plaintiff including the us home d C the downstream enterprises customers。The defendant involving Chinese three dimensional C giant，Including the northeast pharmaceuticals group、North China pharmaceutical、Shijiazhuang subsist pharmaceutical（Belonging to ShiYao group）And China pharmaceutical group, etc。